Japanese drugmaker aims to create coronavirus vaccine fast

27 April 2020
shionogi-big

Osaka, Japan-based pharmaceutical firm Shionogi (TYO: 4507) has announced a new project to develop a vaccine for COVID-19, sending shares in the company up over 3% on Monday.

The firm said it was working with public institutions, academia and partner companies to address COVID-19, including in the pursuit of therapeutics, vaccines, and antibody test kits.

A subsidiary of the company, UMN Pharma, is now working on the discovery and development of a recombinant protein vaccine for COVID-19, using their unique Baculovirus Expression Vector System (BEVS) technology.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology